• where experts go to learn about FDA
  • Year: 2019

    • Teeth, They Must Be Very Much Worthwhile: GAO Report on REMS Abuses Notes Lack of Agency EnforcementNovember 20th, 2019

      The Government Accountability Office released a new Report last week focusing on the oft-analyzed tactics used by some innovator or brand-name pharmaceutical manufacturers to keep generic versions of products off the market.  Like some facets of then-Commissioner Gottlieb’s Drug Competition Action Plan, the GAO Report …

    • U.S. Cattlemen Petition USDA to Address “Made in USA” and “Product of USA” ClaimsNovember 19th, 2019

      On October 23, 2019, the U.S. Cattlemen Association (USCA) petitioned USDA regarding Made in USA and Product of USA and similar claims on beef. USCA explains that it is concerned that voluntary “Made in USA” labeling for beef products, without a clear definition of what constitutes …

    • The Theranos Saga Continues: Court Requires Government to Produce DocumentsNovember 18th, 2019

      On November 5, 2019, the U.S. District Court for the Northern District of California ruled in favor of Theranos founder Elizabeth Holmes and former Theranos president Sunny Balwani, in a battle over access to government documents.  While this represents a small victory for these defendants, …

    • The End May Be Here: Court Grants DOJ Motion to Dismiss Whistleblowers’ FCA SuitNovember 15th, 2019

      On November 5, 2019, the U.S. District Court for the Northern District of California added another entry in the long running saga United States ex rel. Campie v. Gilead Sciences, Inc. when it granted the DOJ’s motion to dismiss.  We have extensively covered this case …

    • FDA Finalizes Guidance on Process to Request Review of CFG DenialNovember 14th, 2019

      FDA is issuing final guidance on how device firms may request review of a decision to withhold issuance of a Certificate to Foreign Government (CFG).  What is a CFG?  In many cases, foreign governments will seek official assurance that products exported to their countries are …

    • HP&M Takes Home Tier 1 FDA Law Ranking Honors from U.S. News and Best LawyersNovember 13th, 2019

      Hyman, Phelps & McNamara, P.C. (“HP&M”) has once again been ranked as a “Tier 1” law firm in the area of “FDA Law” (both nationally and in Washington, D.C.) by the folks over at U.S. News & World Report, who teamed up with Best Lawyers …

    • Gene Therapy Company Sues FDA After Being Placed on Clinical HoldNovember 11th, 2019

      On November 7, 2019, gene therapy company Regenxbio Inc., filed suit in U.S. District Court in Washington, D.C. against FDA asking the court to set aside a partial clinical hold on one clinical trial and a full clinical trial for another.  The complaint also seeks …

    • Will USDA’s Rule Get Hemp Over the Hump? (Maybe Not Without a Little Help from FDA)November 7th, 2019

      USDA published its much-anticipated interim final rule establishing a domestic hemp production program, as directed by the Agriculture Improvement Act of 2018 (a/k/a the Farm Bill).  The rule sets out the requirements for hemp production plans developed by States and Indian Tribes that choose to …

    • FDA Law Alert – November 2019November 6th, 2019

      Hyman, Phelps & McNamara, P.C. is pleased to publish the third installment of the FDA Law Alert, a quarterly newsletter highlighting key postings from our nationally acclaimed FDA Law Blog.  Please subscribe to the FDA Law Blog to receive contemporaneous posts on government regulatory and …

    • Nutrition Labeling Developments: Final Rule Regarding Vending Machine Calorie Labeling and Enforcement DiscretionNovember 5th, 2019

      Final rule regarding vending machine calorie labeling Almost 5 years ago, as part of nutrition labeling requirements under the ACA, FDA issued a final rule which requires operators who own or operate 20 or more vending machines to disclose calorie information for food sold from vending …

    • FDA Does Away with the Compliance Policy Guide for Homeopathic Drug ProductsOctober 29th, 2019

      In two Federal Register notices and the denial of a citizens petition, FDA laid out a revised enforcement program for homeopathic drugs. Under the FDC Act, just as allopathic drug product, homeopathic drug products are subject to new drug requirements related to approval, adulteration, and misbranding. …

    • The High Costs of “Weaponizing” Discovery StrategiesOctober 25th, 2019

      What do you get when you “cross an approach to discovery à la Inspector Clouseau with a corporate lawyer caricature found in cartoon caption contests?” According to Judge Steven Rau of the District of Minnesota in a 32-page order that required an “exhaustive” 15-page factual …

    • When FDA and the Practice of (Tele)Medicine CollideOctober 24th, 2019

      It is generally accepted that FDA’s authority under the Federal Food, Drug, and Cosmetic Act (FDCA) does not allow for FDA to regulate the practice of medicine.  FDCA § 1006 (21 U.S.C. § 396) explicitly states that FDA may not interfere with the practice of medicine …

    • California Chamber of Commerce Files Lawsuit to End Prop. 65 Warnings for Acrylamide on FoodsOctober 23rd, 2019

      On October 8, 2019, the California Chamber of Commerce (CalChamber) filed a lawsuit in federal district court against the State of California requesting that the Court enjoin the State, its agents and private enforcers from requiring Prop. 65 warnings on foods that contain acrylamide.  Plaintiff …

    • CMS and OIG Propose Changes to the Stark Law, Anti-Kickback Statute and Civil Monetary Penalty RuleOctober 22nd, 2019

      In the Federal Register of Thursday, October 17, the Centers for Medicare & Medicaid Services (CMS) and the Department of Health and Human Services (HHS) Office of Inspector General (OIG) both published substantial amendments to the regulations implementing the Medicare physician self-referral law (commonly referred …